Immunotherapy for Renal Cell Carcinoma
Section snippets
Cytokine therapy
Although several cytokines have shown antitumor activity in RCC, the most consistent results have been reported with IL-2 and IFN-α. In contrast to the results seen with molecularly targeted therapies (eg, sorafenib, sunitinib), which lead to tumor shrinkage in most treated patients but do not produce remissions of cancer when therapy is discontinued, the administration of HD IL-2 has consistently produced durable responses in a small percentage of patients with advanced RCC.8, 14, 15 However,
Influence of Histologic Subtype
Responses to immunotherapy are most frequently seen in patients with clear cell RCC.28, 29, 30 This observation was detailed in a retrospective analysis of pathology specimens obtained from 231 patients (163 primary and 68 metastatic tumor specimens) who had received IL-2 therapy in Cytokine Working Group (CWG) clinical trials.30 For patients with primary tumor specimens available for review, the response rate to IL-2 was 21% (30 of 146) for patients with clear cell histologic primary tumors
Current investigation in patient selection
The CWG conducted the high-dose IL-2 Select trial to determine, in a prospective fashion, if the predictive model proposed by Atkins and colleagues32 can identify a group of patients with advanced RCC who are significantly more likely to respond to high-dose IL-2–based therapy (good risk) than a historical, unselected patient population. The preliminary clinical results of this trial revealed a response rate (28%) that was significantly higher that the historical experience with high-dose IL-2.
Combination of immunotherapy and targeted/antiangiogenic therapy
Although the role of low-dose single-agent cytokines is limited, combinations of immunotherapy with vascular endothelial growth factor (VEGF) targeted therapy may have merit. Two recently completed, large phase III trials of IFN plus bevacizumab versus IFN alone have shown superior efficacy with the combination regimen compared with cytokine monotherapy and suggest the potential of an additive effect.
Soon after bevacizumab became the first VEGF targeted agent to show efficacy as monotherapy in
Investigational immunotherapy in RCC tumor vaccines
Metastatic RCC is a setting in which there has been great interest in testing novel immunotherapies. Several such approaches, including vaccination and allogeneic bone marrow transplantation, have been tested over the past 2 decades. The initial reports evaluating allogeneic bone marrow transplantation were encouraging; however, further clinical trials have highlighted the potential toxicity and limited applicability of this approach.6, 42, 43
The use of tumor vaccines has been explored in RCC,
Overcoming obstacles to effective immunotherapy in RCC
An improved understanding of the molecular mechanisms that govern the interaction between a tumor and host immune response has provided insight into why immunotherapies too often fail to achieve satisfactory results. In RCC, obstacles to effective immunotherapy likely include the physiologic downmodulation of the immune response through the increased expression of molecules such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) on the surface of activated T cells, the proliferation of regulatory
Investigational targeted immunotherapy
In a single-institution phase II trial, the CTLA-4 antibody ipilimumab produced major tumor regressions but also significant toxicities in patients with metastatic RCC who had failed previous immunotherapy.104 Toxicities associated with CTLA-4 antibodies, including enteritis, skin rash, and hypophysitis, have occasionally been life threatening and have also been associated with tumor response. Combination of cytokines and agents that block immune downregulation may prove particularly effective
PD-1/PD-L1 biology
The PD-1/PD-L1 pathway is an important inhibitory pathway that regulates T-cell activation and mediates T-cell tolerance (Fig. 2).113 The PD-1 receptor is expressed on T cells, B cells, monocytes, and natural killer T cells after activation. PD-L1 (B7-H1) and PD-L2 (B7-dendritic cell), the 2 ligands for PD-1, are expressed on antigen-presenting cells, including dendritic cells and macrophages. In addition, PD-L1 is expressed on nonhematopoietic cells, including pancreatic islet cells,
PD-1 and tumor immunity
There has been increasing interest in exploring the contribution of the PD-1/PD-L1 pathway to tumor evasion of host immunity. Tumor cells secrete inhibitory cytokines, including TGF-β and IL-10, which creates an immunosuppressive milieu and limits effective antitumor immunity.
Recent studies suggest that tumor expression of PD-L1 may play an important role in contributing to tumor-mediated immunosuppression. A variety of tumors have been shown to express PD-L1, including renal, melanoma,
BMS-936558 in phase I trials
Brahmer and colleagues103 reported the first human phase I/II trial of BMS-936558 (MDX-1106, ONO-4538), a fully human IgG4 anti-PD-1 blocking antibody, in patients with selected refractory or relapsed malignancies. This single-dose trial established the maximum tolerated dose (MTD) of BMS-936558 at 10 mg/kg without evidence of serious toxicity (arthritic symptoms: 2 patients; thyroid-stimulating hormone increase: 1 patient). Flow cytometric analysis showed sustained occupancy of most PD-1
Vaccination plus immune checkpoint blockade
To realize the full potential of a vaccine approach in RCC, combinations with immune stimulants (eg, granulocyte macrophage colony-stimulating factor) and inhibitors of natural T-cell regulation pathways (eg, CTLA4 blockade, T-reg depletion) may be necessary.
The PD-1/PD-L1 pathway may play an important role in blunting immune response to tumor vaccines. PD-1 is upregulated on T-cell populations in response to antigenic and nonantigenic stimulation. Study findings suggest that stimulation with
Combination of investigational immunotherapy and targeted/antiangiogenic therapy
Although VEGF pathway targeted therapies (eg, sunitinib, bevacizumab) have significantly improved outcomes for patients with RCC, disease progression is inevitable. Although the mechanisms of treatment resistance are poorly understood, the immunosuppressive effects of increased VEGF levels and MDSC may play an important role in the process.99, 100, 101 Recent preclinical and correlative investigations have provided new insights into the potentially favorable effect that VEGF receptor TKIs (eg,
Summary
RCC has long been considered an immunologically influenced malignancy and thus served as a platform for the clinical testing of anticancer immunotherapy. The nonspecific cytokines, IL-2 and IFN-α, have undergone the most testing and produced only modest benefits for unselected patients. High-dose IL-2 remains the only approach to produce durable responses in patients with metastatic RCC and can thus be considered in appropriately selected patients. For patients unlikely to benefit from, unable
References (140)
- et al.
Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup
J Urol
(1992) - et al.
A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters
J Urol
(2000) - et al.
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Lancet
(2007) - et al.
Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer
J Urol
(2008) - et al.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial
Lancet
(2004) - et al.
Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma
J Urol
(2002) - et al.
Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings
Mol Ther
(2004) - et al.
Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors
Ann Oncol
(2005) Dendritic cells: development, function and potential use for cancer immunotherapy
Blood Rev
(1999)- et al.
Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma
Clin Immunol
(2007)
Dendritic-cell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma
Lancet Oncol
The emerging role of CTLA-4 as an immune attenuator
Immunity
CTLA-4 can function as a negative regulator of T cell activation
Immunity
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells
Immunity
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group
N Engl J Med
Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer
J Clin Oncol
Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte–macrophage colony-stimulating factor
J Immunother
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
N Engl J Med
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
J Exp Med
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
Cancer J Sci Am
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines
J Clin Oncol
Sorafenib in advanced clear-cell renal-cell carcinoma
N Engl J Med
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
N Engl J Med
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
N Engl J Med
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
J Clin Oncol
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response
Ann Surg
Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy
J Urol
Interferon therapy for the treatment of renal cancer
Cancer
Interferon therapy for renal cell carcinoma
Semin Oncol
Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration
J Clin Oncol
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d’Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer
J Clin Oncol
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators
Lancet
Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
J Clin Oncol
Immunotherapy for advanced renal cell cancer
Cochrane Database Syst Rev
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie
N Engl J Med
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
J Clin Oncol
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
J Clin Oncol
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial
Cancer
Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy
J Clin Oncol
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
J Clin Oncol
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
J Immunother
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy
Clin Cancer Res
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer
Clin Cancer Res
Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma
Proc Am Soc Clin Oncol
The high-dose Aldesleukin (HD IL-2) “SELECT” trial in patients with metastatic renal cell carcinoma (mRCC)
J Clin Oncol
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
N Engl J Med
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
J Clin Oncol
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival
J Clin Oncol
Phase II study of bevacizumab and high dose bolus aldesleukin (IL-2) in metastatic renal cell carcinoma patients: a Cytokine Working Group Study
J Clin Oncol
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer
J Clin Oncol
Cited by (24)
Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma
2016, Cancer Treatment ReviewsPD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
2015, Cancer Treatment ReviewsInterleukin-17D mediates tumor rejection through recruitment of natural killer cells
2014, Cell ReportsCitation Excerpt :In contrast, it has not been shown whether regressor cells can produce cytokines that serve to activate antitumor immunity. Importantly, cytokine-based immune therapy is a mainstay for treatment of human cancers such as melanoma and renal cell carcinoma (Nicholas and Lesinski, 2011; Rosenblatt and McDermott, 2011). In these diseases, treatment with interleukin-2 (IL-2) and interferon α (IFNα) is associated with severe toxic effects that limit therapeutic efficacy (Garbe et al., 2011; Hutson, 2011).
Novel immunotherapeutic strategies in development for renal cell carcinoma
2013, European UrologyCitation Excerpt :According to a recent report, no agent has yet been proven beneficial in the adjuvant setting, although several trials with TKIs are ongoing [4]. However, one recent randomized trial did show that an autologous tumor-cell vaccine administered after surgery produced a modest increase in 5-yr PFS compared with no adjuvant therapy (77.4% vs 67.8%, respectively; p = 0.02) [49]. Results from this study suggest immunotherapy may have a role in the high-risk RCC adjuvant setting and support further evaluation.
Immunotherapy in Renal Diseases
2012, Medical Clinics of North America
Disclosure: Supported in part by the DF/HCC Renal Cancer SPORE: P50 CA101942-01.